Effect of adaptive servo-ventilation for central sleep apnoea in systolic heart failure on muscle sympathetic nerve activity: a SERVE-HF randomised ancillary study.

"Conflict of interest: R. Tamisier reports lecture fees from ResMed, grant support through his institution from ResMed, Agiradom and Philips, and travel grants from Agiradom. J-L. Pépin reports grant support through his institution from ResMed, Agiradom, Vutalaire and Philips, and travel grants from Agiradom. H. Woehrle reports no conflict of interest. M. Salvat reports no conflict of interest. G. Barone-Rochette reports research grants from Merck Sharp and Dohme, Fondation de France, INSERM, Fédération Française de Cardiologie and Société Française de Cardiologie, and consulting fees from Bayer. C. Rocca reports no conflict of interest. E. Vettorazzi reports institutional research grants from ResMed. H. Teschler reports no conflict of interest. M. Cowie reports no conflict of interest. P. Lévy reports no conflict of interest."

"English language editing assistance was provided by Nicola Ryan, an independent medical writer, funded by ResMed, and Alison Foote (Grenoble Alpes University Hospital, Grenoble, France). Collaborators: Caroline Augier, Aude Boignard, Elisabeth Borel, Valentin Cea, Pascal Defaye, Marie Destors, Peggy Jacon, Yannick Neuder, Marianne Noirclerc, Laurent Morin and Andry Rakotovao. Support statement: This work was supported by ResMed, the ResMed Foundation, the endowment fund “Agir pour les maladies chroniques” and the French National Research Agency (ANR) in the framework of the “Investissements d'avenir” programme (ANR-15-IDEX-02). Funding information for this article has been deposited with the Crossref Funder Registry."

"The measurement and analysis of MSNA was a 3-month ancillary study to the SERVE-HF trial conducted in a single centre in Grenoble, France. This ancillary study and the main SERVE-HF trial were approved by the local ethics committee (CPP Sud-Est V, Grenoble, France; 2008-A00414-51/2) and registered at ClinicalTrials.gov (NCT00733343). All participants provided signed informed consent before inclusion in the trial. After the final MSNA study visit, all participants continued to be followed in the main SERVE-HF trial for at least 24 months. The MSNA study protocol was approved by the SERVE-HF steering committee. The trial and ancillary study were conducted in accordance with Good Clinical Practice guidelines and the principles of the 2002 Declaration of Helsinki. This clinical trial was prospectively registered at ClinicalTrials.gov with identifier number NCT00733343. Access to this subset of SERVE-HF study data is reviewed by and approved by the steering committee and study sponsor. For further information, please contact the corresponding author."